Comparison between Mahamaya Lifesciences IPO and Saffron Speciality Papers IPO.
Mahamaya Lifesciences IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Saffron Speciality Papers IPO is a SME Bookbuilding proposed to list at BSE SME.
| Mahamaya Lifesciences IPO | Saffron Speciality Papers IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Oneview Corporate Advisors Pvt.Ltd. | BOI Merchant Bankers Ltd. |
| Registrar | Kfin Technologies Ltd. | NSDL Database Management Ltd. |
| Market Maker | Mansi Share & Stock Broking Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Mahamaya Lifesciences IPO is up to ₹66.91 Cr whereas the issue size of the Saffron Speciality Papers IPO is up to ₹0.00 Cr. The final issue price of Mahamaya Lifesciences IPO is ₹114.00 per share and of Saffron Speciality Papers IPO is .
| Mahamaya Lifesciences IPO | Saffron Speciality Papers IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹108.00 per share | |
| Issue Price (Upper) | ₹114.00 per share | |
| Issue Price (Final) | ₹114.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1200 shares | |
| Fresh Issue Size | 53,29,200 shares | 55,60,000 shares |
| Fresh Issue Size (Amount) | up to ₹60.75 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 5,40,000 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹6.16 Cr | up to ₹0.00 Cr |
| Issue Size Total | 58,69,200 shares | 55,60,000 shares |
| Issue Size Total (Amount) | up to ₹66.91 Cr | up to ₹0.00 Cr |
Mahamaya Lifesciences IPO opens on Nov 11, 2025, while Saffron Speciality Papers IPO opens on . The closing date of Mahamaya Lifesciences IPO and Saffron Speciality Papers IPO is Nov 13, 2025, and , respectively.
| Mahamaya Lifesciences IPO | Saffron Speciality Papers IPO | |
|---|---|---|
| Anchor Bid Date | Nov 10, 2025 | |
| Issue Open | Nov 11, 2025 | |
| Issue Close | Nov 13, 2025 | |
| Basis Of Allotment (Tentative) | Nov 14, 2025 | |
| Initiation of Refunds (Tentative) | Nov 17, 2025 | |
| Credit of Share (Tentative) | Nov 17, 2025 | |
| Listing date (Tentative) | Nov 18, 2025 | |
| Anchor Lockin End date 1 | Dec 13, 2025 | |
| Anchor Lockin End date 2 | Feb 11, 2026 |
Mahamaya Lifesciences IPO P/E ratio is 15.65, as compared to Saffron Speciality Papers IPO P/E ratio of .
| Mahamaya Lifesciences IPO | Saffron Speciality Papers IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Mahamaya Lifesciences Ltd.'s revenue increased by 64% and profit after tax (PAT) rose by 148% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 77.27 | 89.4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 56.35 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 15.65 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹266.82 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 34.94% | 37.48% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 23.15% | 24.06% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.08 | 3.68 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹7.29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 26.19% | 37.48% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Mahamaya Lifesciences IPO Retail Individual Investors (RII) are offered 20,59,200 shares while in Saffron Speciality Papers IPO retail investors are offered 20,59,200 shares. Qualified Institutional Buyers (QIB) are offered 11,76,000 shares in Mahamaya Lifesciences IPO and 0 shares in Saffron Speciality Papers IPO.
| Mahamaya Lifesciences IPO | Saffron Speciality Papers IPO | |
|---|---|---|
| Anchor Investor Reservation | 17,52,000 shares | 0 shares |
| Market Maker Reservation | 3,09,600 shares | 0 shares |
| QIB | 11,76,000 shares | 0 shares |
| NII | 8,82,000 shares | 0 shares |
| RII | 20,59,200 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 58,69,200 shares | 0 shares |
Mahamaya Lifesciences IPO subscribed 1.63x in total, whereas Saffron Speciality Papers IPO subscribed .
| Mahamaya Lifesciences IPO | Saffron Speciality Papers IPO | |
|---|---|---|
| QIB (times) | 1.19x | |
| NII (times) | 3.63x | |
| Big NII (times) | 5.00x | |
| Small NII (times) | 0.90x | |
| RII (times) | 1.02x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 1.63x |
